Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
Fennec Pharmaceuticals Inc. (FENC)
Last fennec pharmaceuticals inc. earnings: 11/12 06:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.fennecpharma.com/investor-relations
Company Research
Source: GlobeNewswire
– Administration of PEDMARK® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) – – Early Signals of Hearing Preservation Highlight the Potential of PEDMARK® to Address Cisplatin-Induced Hearing Loss, a Critical Survivorship Gap, Without Compromising Cisplatin’s Established Antitumor Activity – – Majority of High-Risk Patients Receiving PEDMARK® Demonstrated No Measurable Hearing Loss During or After Treatment Despite Prevalence of Baseline Hearing Impairment – RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced new real world data supporting potential use of PEDMARK® (sodium thiosulfate injection) in adults with head and neck cancers were presented as a digital poster at the 2026 Multidisciplinary Head and Neck Cancers Symposium (MHNCS) in Palm Desert, CA from February 19 – 21, 2026.
Show less
Read more
Impact Snapshot
Event Time:
FENC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FENC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FENC alerts
High impacting Fennec Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
FENC
News
- Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute [Yahoo! Finance]Yahoo! Finance
- Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer InstituteGlobeNewswire
- Fennec Presents Real World Data Supporting Pedmark Use in Treating Adults with Head & Neck Cancers [Yahoo! Finance]Yahoo! Finance
- Adherex Technologies (NASDAQ:FENC) was upgraded by analysts at B.Riley Securit to a "strong-buy" rating.MarketBeat
- Adherex Technologies (NASDAQ:FENC) is now covered by analysts at B. Riley Securities. They set a "buy" rating and a $16.00 price target on the stock.MarketBeat
FENC
Earnings
- 11/13/25 - Beat
FENC
Sec Filings
- 3/5/26 - Form S-8
- 3/4/26 - Form 8-K
- 3/3/26 - Form 4
- FENC's page on the SEC website